Net Income (Loss) Attributable to Parent in USD of GILEAD SCIENCES, INC. from Q1 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Gilead Sciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2010 to Q3 2025.
  • Gilead Sciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $3.05B, a 144% increase year-over-year.
  • Gilead Sciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $8.11B, a 6286% increase year-over-year.
  • Gilead Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $480M, a 91.5% decline from 2023.
  • Gilead Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $5.67B, a 23.4% increase from 2022.
  • Gilead Sciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $4.59B, a 26.2% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

GILEAD SCIENCES, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $8.11B $3.05B +$1.8B +144% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 $6.31B $1.96B +$346M +21.4% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $5.97B $1.32B +$5.49B 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $480M $1.78B +$353M +24.7% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 $127M $1.25B -$927M -42.5% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 $1.05B $1.61B +$569M +54.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $485M -$4.17B -$5.18B -513% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $5.67B $1.43B -$210M -12.8% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 $5.88B $2.18B +$391M +21.9% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $5.48B $1.05B -$99M -8.65% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $5.58B $1.01B +$991M +5216% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $4.59B $1.64B +$1.26B +329% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025
Q3 2022 $3.33B $1.79B -$803M -31% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 $4.14B $1.14B -$378M -24.8% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023
Q1 2022 $4.52B $19M -$1.71B -98.9% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023
Q4 2021 $6.23B $382M -$1.17B -75.4% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2024
Q3 2021 $7.39B $2.59B +$2.23B +620% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022
Q2 2021 $5.16B $1.52B +$4.86B 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 $301M $1.73B +$178M +11.5% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 $123M $1.55B -$1.15B -42.5% 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2021
Q3 2020 $1.27B $360M +$1.53B 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021
Q2 2020 -$257M -$3.34B -$5.22B -278% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $4.96B $1.55B -$424M -21.5% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $5.39B $2.7B +$2.69B 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 $2.69B -$1.17B -$3.26B -156% 01 Jul 2019 30 Sep 2019 10-K 25 Feb 2021
Q2 2019 $5.96B $1.88B +$63M +3.47% 01 Apr 2019 30 Jun 2019 10-K 25 Feb 2021
Q1 2019 $5.89B $1.98B +$437M +28.4% 01 Jan 2019 31 Mar 2019 10-K 25 Feb 2021
Q4 2018 $5.46B $3M* +$3.87B 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2020
Q3 2018 $1.59B $2.1B -$621M -22.8% 01 Jul 2018 30 Sep 2018 10-K 25 Feb 2020
Q2 2018 $2.21B $1.82B -$1.26B -40.9% 01 Apr 2018 30 Jun 2018 10-K 25 Feb 2020
Q1 2018 $3.46B $1.54B -$1.16B -43.1% 01 Jan 2018 31 Mar 2018 10-K 25 Feb 2020
Q4 2017 $4.63B -$3.87B -$6.97B -224% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2019
Q3 2017 $11.6B $2.72B -$612M -18.4% 01 Jul 2017 30 Sep 2017 10-K 26 Feb 2019
Q2 2017 $12.2B $3.07B -$424M -12.1% 01 Apr 2017 30 Jun 2017 10-K 26 Feb 2019
Q1 2017 $12.6B $2.7B -$864M -24.2% 01 Jan 2017 31 Mar 2017 10-K 26 Feb 2019
Q4 2016 $13.5B $3.11B -$1.58B -33.6% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2018
Q3 2016 $15.1B $3.33B -$1.27B -27.6% 01 Jul 2016 30 Sep 2016 10-K 27 Feb 2018
Q2 2016 $16.3B $3.5B -$995M -22.2% 01 Apr 2016 30 Jun 2016 10-K 27 Feb 2018
Q1 2016 $17.3B $3.57B -$767M -17.7% 01 Jan 2016 31 Mar 2016 10-K 27 Feb 2018
Q4 2015 $18.1B $4.68B +$1.2B +34.3% 01 Oct 2015 31 Dec 2015 10-K 27 Feb 2017
Q3 2015 $16.9B $4.6B +$1.87B +68.4% 01 Jul 2015 30 Sep 2015 10-K 27 Feb 2017
Q2 2015 $15B $4.49B +$836M +22.9% 01 Apr 2015 30 Jun 2015 10-K 27 Feb 2017
Q1 2015 $14.2B $4.33B +$2.11B +94.6% 01 Jan 2015 31 Mar 2015 10-K 27 Feb 2017
Q4 2014 $12.1B $3.49B +$2.7B +341% 01 Oct 2014 31 Dec 2014 10-K 24 Feb 2016
Q3 2014 $9.41B $2.73B +$1.94B +246% 01 Jul 2014 30 Sep 2014 10-K 24 Feb 2016
Q2 2014 $7.46B $3.66B +$2.88B +373% 01 Apr 2014 30 Jun 2014 10-K 24 Feb 2016
Q1 2014 $4.58B $2.23B +$1.51B +208% 01 Jan 2014 31 Mar 2014 10-K 24 Feb 2016
Q4 2013 $3.08B $791M +$28.5M +3.73% 01 Oct 2013 31 Dec 2013 10-K 25 Feb 2015
Q3 2013 $3.05B $789M +$113M +16.8% 01 Jul 2013 30 Sep 2013 10-K 25 Feb 2015
Q2 2013 $2.93B $773M +$61.4M +8.63% 01 Apr 2013 30 Jun 2013 10-K 25 Feb 2015
Q1 2013 $2.87B $722M +$280M +63.4% 01 Jan 2013 31 Mar 2013 10-K 25 Feb 2015
Q4 2012 $2.59B $763M +$97.4M +14.6% 01 Oct 2012 31 Dec 2012 10-K 25 Feb 2014
Q3 2012 $2.49B $676M +$234M +52.8% 01 Jul 2012 30 Sep 2012 10-K 25 Feb 2014
Q2 2012 $2.26B $712M -$34.7M -4.65% 01 Apr 2012 30 Jun 2012 10-K 25 Feb 2014
Q1 2012 $2.3B $442M -$209M -32.1% 01 Jan 2012 31 Mar 2012 10-K 25 Feb 2014
Q4 2011 $2.5B $665M +$35.7M +5.68% 01 Oct 2011 31 Dec 2011 10-K 27 Feb 2013
Q3 2011 $2.47B $442M -$263M -37.3% 01 Jul 2011 30 Sep 2011 10-Q 08 May 2013
Q2 2011 $2.73B $746M +$34.2M +4.8% 01 Apr 2011 30 Jun 2011 10-K 27 Feb 2013
Q1 2011 $2.7B $651M -$204M -23.8% 01 Jan 2011 31 Mar 2011 10-K 27 Feb 2013
Q4 2010 $2.9B $629M 01 Oct 2010 31 Dec 2010 10-K 23 Feb 2012
Q3 2010 $705M 01 Jul 2010 30 Sep 2010 10-K 23 Feb 2012
Q2 2010 $712M 01 Apr 2010 30 Jun 2010 10-K 23 Feb 2012
Q1 2010 $855M 01 Jan 2010 31 Mar 2010 10-K 23 Feb 2012

GILEAD SCIENCES, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $480M -$5.19B -91.5% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 $5.67B +$1.07B +23.4% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 $4.59B -$1.63B -26.2% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025
2021 $6.23B +$6.1B +4961% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2024
2020 $123M -$5.26B -97.7% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023
2019 $5.39B -$69M -1.27% 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022
2018 $5.46B +$827M +17.9% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 $4.63B -$8.87B -65.7% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2020
2016 $13.5B -$4.61B -25.4% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019
2015 $18.1B +$6.01B +49.6% 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018
2014 $12.1B +$9.03B +294% 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017
2013 $3.08B +$483M +18.6% 01 Jan 2013 31 Dec 2013 10-K 24 Feb 2016
2012 $2.59B -$212M -7.55% 01 Jan 2012 31 Dec 2012 10-K 25 Feb 2015
2011 $2.8B -$97.6M -3.37% 01 Jan 2011 31 Dec 2011 10-K 25 Feb 2014
2010 $2.9B 01 Jan 2010 31 Dec 2010 10-K 27 Feb 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.